Hangzhou Tigermed Consulting Co., Ltd.

Exhibition concludes with 105,000 attendees confirmed over three days Winner of prestigious Vision NextGen startup competition revealed as X-Genome, an innovative biotech business focused on education Latest deals and MoUs announced on site totalling USD 13.3bn - including a cooperation agreement between the Health Holding Company and Huawei and a partnership between the Council of Health Insurance and the Johns Hopkins Center Leaders' Summit presented a visionary look at the state of global healthcare in 2040 - including the emergence of advanced robotics and AI as central to mainstream healthcare delivery Focus on women's health saw leading experts discuss increasing the value healthcare services bring to women in multiple countries, with themes of technology, mental health and accessibility to services RIYADH, Saudi Arabia, Oct. 24, 2024 /PRNewswire/ -- On its final day, Global Health Exhibition turned its focus to a new generation of health technology innovators with the winner of the event's Vision NextGen competition announced as local biotech business X-Genome. A series of Memorandums of Understanding (MoU) signings and the future of women's health, brought the Exhibition to a successful conclusion. X-Genome is the first genomics training facility for health and scientific professionals in Saudi Arabia, delivering world class educational programs in molecular genetics and cancer cell diseases with the goal of equipping a new generation of professionals to support patients with future technology. The third day marked the establishment of fresh MoUs, partnerships and deals totalling USD 13.3bn. These included a cooperation agreement between the Saudi State-owned Health Holding Company and Huawei, as well as a partnership agreement between the Council of Health Insurance and the Johns Hopkins Center. MoUs were signed between the Saudi Arabia Ministry of Health and Ascend Solutions, AlRamz Medical Company and GSK. In addition, an attendance of more than 105,000 was confirmed over the three days of Global Health Exhibition, representing 35,000 people per day. The Exhibition also saw a 72 percent increase in international attendance from over 138 countries. It featured 1,240 exhibiting brands, four times more than last year, with more than fifty percent of those brands being international. The future of women's healthcare was also a highlight on day three, under the heading 'Wellness and Beyond'. Sessions highlighted the under representation of women in clinical studies and research as well as significant gaps in access to screening for certain cancers. Also noted was the growing global challenge to redesign health systems to meet the mental health needs of women and the role of emerging technologies to achieve this. "In disease prevention for women, there is not enough being done to provide cancer screening," said Dr Ritu Garg, Chief Growth & Innovation Officer, Fortis Healthcare. "We are seeing an explosion in cancer cases worldwide. Beyond this, mental health issues are likely to reach epidemic proportions in the coming years. We require scaleable, technology-driven solutions to meet this challenge." Looking further ahead, the Leaders' Summit considered the state of healthcare services in 2040 and how recognized health challenges today are projected to grow exponentially. "We are looking at a world with five billion chronic disease patients in 2040, from a global population of eight billion," said Reenita Das, Partner, Senior Vice President, Healthcare & Life Sciences, Frost & Sullivan. "In the connected age, what's needed are personalized digital tools, which support what I term the 'IKEA-ization of healthcare'. This means, a world where every individual becomes the CEO of his or her health to manage their own wellbeing, utilizing apps and wearables - turning patients into consumers. "We are on the road to curing cancer, in the same way that we have collectively all but eradicated HIV, but other threats remain on the horizon, including new infectious diseases and 'super bugs', which will continue to proliferate around the world. Advanced technology has a role to play here too, with AI becoming ubiquitous." The Digital Health Forum included a panel on harnessing the power of digitized data for enhanced patient care. "In 2024, a live-stream connected King Faisal Hospital with 600 cardiac surgeons at 300 hospitals virtually, as I performed complex robotic procedures," said Prof Feras Khaliel, Consultant, Cardiac Surgery, King Faisal Specialist Hospital and Research Center. "It was an educational tool. Surgeons were not only observing but in constant communication to ask questions. We have made advances, not only in diagnosis and treatments, but in 3D monitoring for the patient during surgery." Global Health Exhibition Foundation Partner Lean also commented on the event: "Lean is thrilled to be part of Saudi Arabia's groundbreaking journey in innovation towards a healthier nation," said Hisham Al-Falih, Co-founder and CEO, Lean. "We're excited to share how our cutting-edge solutions are reshaping healthcare, easing access to and powering a healthier, tech-driven future for the Kingdom." "Cultivating the next generation of healthcare talent is a defining goal of Global Health Exhibition, and the exceptional skill and ability shown across the high number of entries to the Vision NextGen competition gives us confidence we are in safe hands," said Rachel Sturgess, Group Director, Tahaluf. "Global Health Exhibition 2024 featured 1,240 exhibiting brands, four times more than last year, with more than fifty percent of those brands being international. The show has doubled in size, to 80,000 square meters, the size of 11 football fields." SOURCE Global Health Exhibition WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Investigative studies are underway testing Ketamir-2 as the potential first at home ketamine analog treatment for PTSD, depression, and neuropathic pain, including cancer pain MIAMI, May 20, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications. Continue Reading MIRA continues to advance studies of Ketamir-2 in animal studies while improving manufacturing optimization as the company prepares for human testing in 2025. Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2 Post this MIRA anticipates that positive results from these preclinical studies will enable the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) by the end of this year, which if cleared by FDA would allow for human clinical testing of Ketamir-2. Development Update: Initiation of Preclinical Trials with Pharmaseed for PTSD MIRA has initiated a preclinical trial in collaboration with Pharmaseed Ltd ("Pharmaseed") to evaluate the efficacy of Ketamir-2 as compared with Ketamine in a rat model of severe PTSD. This study, designed to assess the alleviation of symptoms of chronic stress and behavioral consequences of dysfunctional processing of fear and fear memory, leverages established models demonstrating the effectiveness of ketamine in treating PTSD symptoms. While ketamine has demonstrated rapid and sustained reduction in PTSD symptoms in several clinical studies, it has to be given through intravenous, intramuscular or intranasal administration. The current study is designed to provide robust data on the potential for the orally administered Ketamir-2 through behavioral tests, biomarker analysis, and immunohistochemistry to support future clinical applications. Ongoing studies at Pharmaseed are already exploring the potential of Ketamir-2 in treating depression and several forms of pain, including neuropathic pain. Head-to-Head Preclinical Study to be Conducted by Biotrial, Inc. for Locomotor Activity Evaluation of Ketamir-2 Compared to Ketamine In parallel, MIRA has initiated a study with Biotrial, Inc. (Biotrial) to evaluate the acute effects of Ketamir-2 on spontaneous locomotor activity in mice. This study will assess Ketamir-2's impact compared to ketamine and a control vehicle, providing crucial data on the pharmacodynamics of Ketamir-2. Ketamine is known to produce a biphasic effect on locomotion (meaning high and low doses of ketamine have very different effects). The initial hypolocomotion (reduced movement) phase observed in rodents after ketamine administration is consistent with the sedative and dissociative effects reported with ketamine in humans, which can lead to impaired coordination and motor function. The subsequent hyperlocomotion (increased movement) phase in rodents mirrors the agitation, confusion and psychotic effects seen in humans, particularly at higher doses of ketamine. Since Ketamir-2 has a different chemical profile that ketamine, MIRA anticipates that these head-to-head studies can be predictive of Ketamir-2's side-effect profile in humans. Initiation of 7-Day Animal Studies with Frontage MIRA is also advancing towards regulatory IND-enabling study and has also initiated 7-day rat and dog toxicology studies with Frontage Laboratories. These studies are critical steps towards ensuring the safety and efficacy of Ketamir-2 in preparation for human clinical trials. Advancements in Ketamir-2 Manufacturing In recent weeks, MIRA has also made significant advancements in the manufacturing process of Ketamir-2, markedly simplifying and optimizing the synthetic process while reducing production costs and overall cost of goods. These improvements are critical as MIRA scales up production under Good Manufacturing Practices (GMP) to enable the required regulatory toxicology studies and to prepare for an IND for Ketamir-2 submission later this year. Potential of Ketamir for PTSD Treatment According to the National Institutes of Health, PTSD affects approximately 8 million adults annually in the United States, with current treatments often providing limited relief and significant side effects. Ketamir-2, as an oral ketamine analog, offers a promising alternative due to its potential for ultra-rapid antidepressant effects and improved safety profile. Unlike traditional SSRIs and benzodiazepines, Ketamir-2 targets NMDA receptors in the brain, which play a crucial role in synaptic plasticity and cognitive function, potentially offering more effective and faster relief from PTSD symptoms. Exploring Collaborations for Cancer Pain Studies In addition to its current initiatives, MIRA is also in discussions with several research centers to potentially collaborate on studying Ketamir-2's efficacy in treating cancer pain. These collaborations could expedite the IND submission for Ketamir-2 and the commencement of human clinical trials, while increasing the potential therapeutic applications of Ketamir-2. Management Comments Erez Aminov, Chairman and CEO of Mira Pharmaceuticals, commented, "The initiation of these preclinical trials represents a significant milestone in our mission to develop next-generation treatments for severe mental health disorders as well as neuropathic pain. Our collaboration with Pharmaseed and Biotrial underscores our commitment to advancing Ketamir-2 towards clinical development in humans and addressing the urgent needs of those suffering from PTSD and other debilitating conditions. The financial impact of medication-treated major depressive disorder in the U.S. stands at an overwhelming $92.7 billion annually, with $43.8 billion (47.2%) of this amount due to treatment-resistant depression1. Additionally, the U.S. market for post-traumatic stress disorder treatments is on a significant rise, projected to reach $26 billion by 20312. We are hopeful that Ketamir-2 can help address these critical public health issues." Dr. Itzchak Angel, Chief Scientific Advisor of Mira Pharmaceuticals, added, "The data generated from these studies will be invaluable in demonstrating Ketamir-2's potential benefits. What sets Ketamir-2 apart from ketamine is its high oral bioavailability and lack of mu opioid interaction. As a result, Ketamir-2 potentially offers a safer and more effective option for oral administration, providing rapid relief for depression in a home setting. We are excited about the progress we have made in simplifying the drug's manufacturing process and are hopeful that Ketamir-2 can offer new hope for patients with PTSD and other mental health and pain conditions." About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian and Mexican rights for Ketamir-2, a novel, patent pending oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation and post-traumatic stress disorder. The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations. In addition, MIRA's novel oral pharmaceutical marijuana, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. Additional information about the Company is available at: . Ketamir-2 and MIRA-55 are in early stage pre-clinical development. There is no assurance that the products will proceed through development or will receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "Aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding Ketamir-2's potential in treating certain mental health conditions or neuropathic pain and statements regarding the timing for the Company's preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results (including the anticipated benefits of the Company's pre-clinical testing and pre-clinical data discussed herein) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at and the Company's website at . The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. SOURCE MIRA Pharmaceuticals, Inc.

Ketamir-2 is a potential treatment for certain major mental health disorders impacting millions of people in the U.S. MIAMI, April 2, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today shares updates on the ongoing pre-clinical studies of its investigational compound, Ketamir-2, a novel oral ketamine analog which could potentially deliver ultra-rapid antidepressant effects. MIRA is conducting pre-clinical studies of Ketamir-2 in collaboration with Frontage Laboratories as a potential treatment for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD). MIRA is hopeful that the encouraging results of these most recent studies will enable MIRA to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration by the end of this year which, if accepted, would allow for human testing of Ketamir-2. The latest in vitro research focused on Ketamir-2's stability in the bloodstream, its metabolism (processing by the body), and how it binds to proteins in the blood. These factors play a crucial role in determining a drug's adequacy and likelihood for acceptable safety, its pharmacological profile and potential modes of administration to patients. Blood Stability and Distribution: Ketamir-2 demonstrated excellent stability in blood from various species, including humans. This means that once in the bloodstream, Ketamir-2 remains unchanged for a sufficient duration, allowing it to potentially exert its therapeutic effects effectively. Metabolic Profile: The studies indicate the potential for Ketamir-2 to be metabolized effectively and safely. The clear identification of specific liver enzymes hints at the potential for Ketamir-2 having fewer interactions with other medications, addressing a common concern among doctors and patients. Protein Binding: Ketamir-2 appears to bind optimally to blood proteins, which suggests the potential for effective delivery throughout the body. This property is crucial for distributing the drug to brain areas where it can exert its effects. Safety Profiles: Initial toxicology assessments provide a favorable safety profile crucial for advancement through regulatory review and clinical trials. Erez Aminov, Chairman & CEO of Mira Pharmaceuticals, shared, "The financial impact of medication-treated major depressive disorder in the U.S. stands at an overwhelming $92.7 billion annually, with $43.8 billion (47.2%) of this amount due to treatment-resistant depression1. Additionally, the U.S. market for post-traumatic stress disorder treatments is on a significant rise, projected to reach $26 billion by 20312. In short, we are facing a mental health crisis in the U.S., and at MIRA Pharmaceuticals, we are developing Ketamir-2 to address these substantial market and medical needs." Itzchak Angel, Ph.D., MIRA's Chief Scientific Advisor, added, "The data we have obtained from these studies is invaluable. They not only enhance our understanding of Ketamir-2 but also underscore its potential benefits for patients with TRD and PTSD and pave the way for what we believe will be straight forward IND-enabling development." 1 The Journal of Clinical Psychiatry, PMID: 33989464 2 Allied Market Research: Post-Traumatic Stress Disorder Treatment Market Research, 2031 About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian and Mexican rights for Ketamir-2, a novel, patent pending oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation and post-traumatic stress disorder. The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations. In addition, MIRA's novel oral pharmaceutical marijuana, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. Additional information about the Company is available at: . Cautionary Note Regarding Forward-Looking Statements This press release and the statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "Aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding Ketamir-2's potential in treating certain mental health conditions. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results (including the anticipated benefits of the Company's pre-clinical testing and pre-clinical data discussed herein) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at and the Company's website at . The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. SOURCE MIRA Pharmaceuticals, Inc.